Loading...

ARTL ARTELO BIOSCIENCES INC Management Changes 8-K Filing

RTL

RTL

ARTELO BIOSCIENCES INC

(ARTL)

2025 8-K

Termination Notice

Regained Compliance

Fundraising Announcement

Funding Agreement

New Bridge Financing

Stock Split Update

Stock Split Announcement

Equity Purchase Agreement

Listing Compliance Update

Annual Meeting Results

Delisting Notice

Annual Meeting Update

Delisting Notice

Bylaw Amendments

Funding Announcement

Management Changes

Cooperation Agreement

Stock Offering Announcement

Stock Offering Update

Bylaw Amendments

Stock Offering Announced

Cancer Treatment Progress

Stockholder Meeting Results

Termination Agreements

Equity Offerings

Equity Offerings

Convertible Debt

Equity Offerings

Non-Compliance with Listing...

Equity Offerings

Not in compliance with list...

Annual Meeting Results

Amendment of Options

Compensation Increase

Bylaws Amendment

Regulation FD Disclosure

External Links:

On October 26, 2025, Artelo Biosciences, Inc. appointed Mark Spring as Chief Financial Officer, effective November 1, 2025, with a base salary of $250,000 and performance-based bonuses; Gregory Gorgas' employment agreement was also amended to enhance severance benefits.

AI Assistant

ARTELO BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.